Posted On: 10/07/2015 3:40:25 PM
Post# of 30066
The Georgetown deal is probably dead unless AMBS pulls off a DX transaction. Their agreement with Georgetown mandated that AMBS meet a bunch of requirements that would be pretty hard to pull off without one. I could be wrong but I don't believe they have ever mentioned that CLIA validation of the Georgetown test was forthcoming. They only mention working to validate the technology. And January is coming soon.
"Amarantus will be required to achieve timely milestones including providing Georgetown with development and commercialization plans for the biomarkers, share information related to Amarantus' diagnostic assets, CLIA validation of biomarkers, recruitment of a senior executive to lead Amarantus' diagnostics division and other requirements as defined in the agreement."
"Amarantus will be required to achieve timely milestones including providing Georgetown with development and commercialization plans for the biomarkers, share information related to Amarantus' diagnostic assets, CLIA validation of biomarkers, recruitment of a senior executive to lead Amarantus' diagnostics division and other requirements as defined in the agreement."
Quote:
In regards to DX transaction, you would think they would be pushing to ink that before Georgetown payment due? I would think the buyer would want to acquire the rights to license & AMBS surely would not want to dilute to pay for that prior.
(0)
(0)
